Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Identifieur interne : 001107 ( PubMed/Corpus ); précédent : 001106; suivant : 001108Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Auteurs : Caroline Prunier ; Pierre Payoux ; Denis Guilloteau ; Sylvie Chalon ; Bruno Giraudeau ; Cynthia Majorel ; Mathieu Tafani ; Erwan Bezard ; Jean-Paul Esquerré ; Jean-Louis BaulieuSource :
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine [ 0161-5505 ] ; 2003.
English descriptors
- KwdEn :
- Aged, Dopamine Plasma Membrane Transport Proteins, Female, Humans, Iodine Radioisotopes, Male, Membrane Glycoproteins, Membrane Transport Proteins (analysis), Middle Aged, Nerve Tissue Proteins, Nortropanes, Parkinson Disease (diagnostic imaging), Parkinson Disease (metabolism), Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , analysis : Membrane Transport Proteins.
- chemical : Dopamine Plasma Membrane Transport Proteins, Iodine Radioisotopes, Membrane Glycoproteins, Nerve Tissue Proteins, Nortropanes.
- diagnostic imaging : Parkinson Disease.
- metabolism : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Tomography, Emission-Computed, Single-Photon.
Abstract
(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methyl-phenyl) nortropane (PE2I), a cocaine analog, is a new, highly specific tracer for imaging dopamine transporter labeled with (123)I for in vivo SPECT. Its reversible binding on dopamine transporter and its rapid kinetics allow quantification of its binding potential according to a 3-compartment model. For quantification of distribution volume of reversible tracer, Logan developed a noninvasive and graphical method that allows accurate estimation of binding potential. In this study, we performed (123)I-PE2I SPECT on healthy volunteers and patients with Parkinson's disease (PD) to validate the Logan graphical method for quantification of (123)I-PE2I binding and to analyze the relationship between (123)I-PE2I SPECT and clinical features of this frequent degenerative disease.
PubMed: 12732666
Links to Exploration step
pubmed:12732666Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.</title><author><name sortKey="Prunier, Caroline" sort="Prunier, Caroline" uniqKey="Prunier C" first="Caroline" last="Prunier">Caroline Prunier</name><affiliation><nlm:affiliation>Nuclear Medicine Department, Institut National de la Santé et de la Recherche Médicale Unit 316, Bretonneau Hospital, Tours, France. c.prunier@chu-tours.fr</nlm:affiliation></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name></author><author><name sortKey="Giraudeau, Bruno" sort="Giraudeau, Bruno" uniqKey="Giraudeau B" first="Bruno" last="Giraudeau">Bruno Giraudeau</name></author><author><name sortKey="Majorel, Cynthia" sort="Majorel, Cynthia" uniqKey="Majorel C" first="Cynthia" last="Majorel">Cynthia Majorel</name></author><author><name sortKey="Tafani, Mathieu" sort="Tafani, Mathieu" uniqKey="Tafani M" first="Mathieu" last="Tafani">Mathieu Tafani</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Esquerre, Jean Paul" sort="Esquerre, Jean Paul" uniqKey="Esquerre J" first="Jean-Paul" last="Esquerré">Jean-Paul Esquerré</name></author><author><name sortKey="Baulieu, Jean Louis" sort="Baulieu, Jean Louis" uniqKey="Baulieu J" first="Jean-Louis" last="Baulieu">Jean-Louis Baulieu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12732666</idno><idno type="pmid">12732666</idno><idno type="wicri:Area/PubMed/Corpus">001107</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001107</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.</title><author><name sortKey="Prunier, Caroline" sort="Prunier, Caroline" uniqKey="Prunier C" first="Caroline" last="Prunier">Caroline Prunier</name><affiliation><nlm:affiliation>Nuclear Medicine Department, Institut National de la Santé et de la Recherche Médicale Unit 316, Bretonneau Hospital, Tours, France. c.prunier@chu-tours.fr</nlm:affiliation></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Guilloteau, Denis" sort="Guilloteau, Denis" uniqKey="Guilloteau D" first="Denis" last="Guilloteau">Denis Guilloteau</name></author><author><name sortKey="Chalon, Sylvie" sort="Chalon, Sylvie" uniqKey="Chalon S" first="Sylvie" last="Chalon">Sylvie Chalon</name></author><author><name sortKey="Giraudeau, Bruno" sort="Giraudeau, Bruno" uniqKey="Giraudeau B" first="Bruno" last="Giraudeau">Bruno Giraudeau</name></author><author><name sortKey="Majorel, Cynthia" sort="Majorel, Cynthia" uniqKey="Majorel C" first="Cynthia" last="Majorel">Cynthia Majorel</name></author><author><name sortKey="Tafani, Mathieu" sort="Tafani, Mathieu" uniqKey="Tafani M" first="Mathieu" last="Tafani">Mathieu Tafani</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Esquerre, Jean Paul" sort="Esquerre, Jean Paul" uniqKey="Esquerre J" first="Jean-Paul" last="Esquerré">Jean-Paul Esquerré</name></author><author><name sortKey="Baulieu, Jean Louis" sort="Baulieu, Jean Louis" uniqKey="Baulieu J" first="Jean-Louis" last="Baulieu">Jean-Louis Baulieu</name></author></analytic><series><title level="j">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</title><idno type="ISSN">0161-5505</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Female</term><term>Humans</term><term>Iodine Radioisotopes</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins (analysis)</term><term>Middle Aged</term><term>Nerve Tissue Proteins</term><term>Nortropanes</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (metabolism)</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term><term>Iodine Radioisotopes</term><term>Membrane Glycoproteins</term><term>Nerve Tissue Proteins</term><term>Nortropanes</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methyl-phenyl) nortropane (PE2I), a cocaine analog, is a new, highly specific tracer for imaging dopamine transporter labeled with (123)I for in vivo SPECT. Its reversible binding on dopamine transporter and its rapid kinetics allow quantification of its binding potential according to a 3-compartment model. For quantification of distribution volume of reversible tracer, Logan developed a noninvasive and graphical method that allows accurate estimation of binding potential. In this study, we performed (123)I-PE2I SPECT on healthy volunteers and patients with Parkinson's disease (PD) to validate the Logan graphical method for quantification of (123)I-PE2I binding and to analyze the relationship between (123)I-PE2I SPECT and clinical features of this frequent degenerative disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12732666</PMID><DateCreated><Year>2003</Year><Month>05</Month><Day>06</Day></DateCreated><DateCompleted><Year>2003</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>663-70</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methyl-phenyl) nortropane (PE2I), a cocaine analog, is a new, highly specific tracer for imaging dopamine transporter labeled with (123)I for in vivo SPECT. Its reversible binding on dopamine transporter and its rapid kinetics allow quantification of its binding potential according to a 3-compartment model. For quantification of distribution volume of reversible tracer, Logan developed a noninvasive and graphical method that allows accurate estimation of binding potential. In this study, we performed (123)I-PE2I SPECT on healthy volunteers and patients with Parkinson's disease (PD) to validate the Logan graphical method for quantification of (123)I-PE2I binding and to analyze the relationship between (123)I-PE2I SPECT and clinical features of this frequent degenerative disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eight PD patients (3 women, 5 men; mean age, 64 +/- 7.9 y; disease duration range, 1-8 y, Hoehn and Yahr stage range, 1-2.5) and 8 age-matched healthy volunteers (4 women, 4 men; mean age, 61.5 +/- 9.5 y) were included in 2 centers and studied with SPECT. Four sequential SPECT imaging sessions of 15-min duration were performed from 5 to 65 min after bolus injection of 140 +/- 30 MBq of (123)I-PE2I.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The kinetics of PE2I in healthy volunteers and PD patients were rapid, and the Logan graphical method allowed quantification of distribution volume ratio (DVR) in the caudate nucleus and putamen. (123)I-PE2I striatal specific binding was significantly reduced in PD patients, compared with healthy volunteers, in the caudate and putamen. The decrease of DVR in the putamen was significantly and inversely correlated to disease duration and Hoehn and Yahr stage. In asymmetric PD patients, (123)I-PE2I uptake was significantly more reduced in the putamen contralateral to the side with predominant clinical symptoms. However, (123)I-PE2I uptake was also significantly reduced in the ipsilateral putamen, compared with that in healthy volunteers, suggesting that (123)I-PE2I SPECT can detect nigrostriatal degeneration before the appearance of clinical symptoms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data indicate that the Logan graphical method is accurate for noninvasive quantification of PE2I and that (123)I-PE2I SPECT is a useful quantitative method for accurate estimation of nigrostriatal dopaminergic nerve terminal degeneration. The close relationships between SPECT findings and clinical data suggest that this method is useful for objectively following the progression of PD and for assessing the effect of potential neuroprotective treatments. Finally, our findings suggest that (123)I-PE2I SPECT can be used for preclinical and early diagnosis of PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prunier</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, Institut National de la Santé et de la Recherche Médicale Unit 316, Bretonneau Hospital, Tours, France. c.prunier@chu-tours.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payoux</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Guilloteau</LastName><ForeName>Denis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chalon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Giraudeau</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Majorel</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tafani</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Esquerré</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Baulieu</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C113010">N-(3-iodoprop-2-enyl)-2-beta-carbomethoxy-3-(4-methylphenyl)nortropane</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009662">Nortropanes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007457" MajorTopicYN="Y">Iodine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009662" MajorTopicYN="Y">Nortropanes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12732666</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001107 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001107 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:12732666
|texte= Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:12732666" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |